Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea, or SGLT-2 inhibitor) SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascular risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%)
The needle is inserted at a 45-degree angle, just below the skin, as opposed to deep into a muscle
Shots work quickly because they skip digestion, and a plan built around bloodwork helps you get the most from each one
No published human clinical trials exist for 5-Amino-1MQ, and products sold online are unverified for purity, dosage, and safety
Before arriving in San Pedro de Atacama, we will watch the sunset over the desert, which is a spectacle to behold